Randomized trial · people
SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large placebo-controlled trial, elamipretide was tolerated well but did not improve walking distance or fatigue over 24 weeks in primary mitochondrial myopathy.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 218
- Published
- 2023
- Journal
- Neurology
What they tested
The team tested whether elamipretide improves walking ability and fatigue in people with primary mitochondrial myopathy, a group of inherited conditions that harm how mitochondria make energy.
How the study was done
A phase 3, randomized, double-blind, placebo-controlled trial in 218 people with genetically confirmed primary mitochondrial myopathy. Half got 40 mg/d of elamipretide and half got placebo (a dummy shot), both under the skin, for 24 weeks.

What they found
Elamipretide missed both of the trial's main goals. On the 6-minute walk test, the gap in distance change between the elamipretide and placebo groups was -3.2 meters (95% CI -18.7 to 12.3; p = 0.69), so the groups did not differ in a meaningful way. On a fatigue questionnaire built for this condition, the gap between groups in the change in total score was -0.07 (p = 0.37), again not a meaningful difference. The drug was tolerated well, and most side effects were mild or moderate.
What it doesn’t show
The trial lasted 24 weeks and tested a single dose in people with this specific genetic muscle condition, and 94% of them were White. It does not show how elamipretide does in other conditions or over longer periods.
The paper
Karaa et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.